Bavarian Nordic
Logotype for Bavarian Nordic

Bavarian Nordic (BAVA) investor relations material

Bavarian Nordic Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Bavarian Nordic
Q3 2026 earnings summary13 Nov, 2026

Executive summary

  • 9M revenue was DKK 4,897m, up 2.2%; Travel Health growth offset lower Public Preparedness revenue. EBITDA was DKK 1,711m, with a 34.9% margin.

  • Rabies-led Travel Health growth and Public Preparedness deliveries supported results; FY2026 guidance was maintained.

  • Strategic priorities, investment and capital allocation are under review, with an update planned for H1 2027.

Financial highlights

  • Q3 revenue was DKK 1,805m, up 0.6%; 9M revenue was DKK 4,897m, up 2.2%. 9M organic growth exceeded 9% excluding discontinued partnerships and FX.

  • Q3 gross margin was 51.9%, versus 49.8% a year earlier; 9M gross margin was 54.0%, versus 51.9%.

  • Q3 EBITDA was DKK 621m, with a 34.4% margin; 9M EBITDA was DKK 1,711m, with a 34.9% margin.

  • 9M operating cash flow was DKK 489m and free cash flow DKK 68m; period-end cash and securities totaled DKK 2,984m.

Outlook and guidance

  • FY2026 revenue guidance remains DKK 6,100m: DKK 3,400m Travel Health, DKK 2,500m Public Preparedness and DKK 200m other revenue; EBITDA margin guidance is 32%.

  • Guidance assumes R&D costs of DKK 750m, CAPEX of DKK 250m and Vimkunya revenue of DKK 200m.

  • Travel Health seasonality and Public Preparedness order timing may drive revenue and EBITDA variability; Travel Health Q4 margin may also reflect back-end-loaded R&D and sales and marketing investment.

  • DKK 2,400m of 2026 Public Preparedness orders and DKK 900m of 2027 orders were secured; medium-term base guidance remains DKK 1.5bn–DKK 2bn.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Bavarian Nordic earnings date

Logotype for Bavarian Nordic
Q4 202611 Mar, 2027
Bavarian Nordic
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Bavarian Nordic earnings date

Logotype for Bavarian Nordic
Q4 202611 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Bavarian Nordic is a clinical-stage biopharmaceutical company that develops and commercializes life-saving vaccines in the areas of cancer and infectious diseases. Its fast-growing portfolio today includes Aeras, an influenza vaccine that has been approved in the United States, Europe, and Canada, and the company is advancing a pipeline of novel, next generation vaccines designed to complement its portfolio. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.